Prothena Corporation plc

NasdaqGS:PRTA Stock Report

Market Cap: US$399.9m

Prothena Management

Management criteria checks 2/4

Prothena's CEO is Gene Kinney, appointed in Sep 2016, has a tenure of 8.67 years. total yearly compensation is $7.23M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $95.06K. The average tenure of the management team and the board of directors is 7.9 years and 8.7 years respectively.

Key information

Gene Kinney

Chief executive officer

US$7.2m

Total compensation

CEO salary percentage9.05%
CEO tenure8.7yrs
CEO ownership0.02%
Management average tenure7.9yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet

Apr 02
Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
author-image

AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities

Mar 26 Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.

Prothena Corporation: Multiple Failures Make It Risky

Mar 03

Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think

Feb 22
Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think

Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price

Jan 24
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price

Prothena Surges After Parkinson's Drug Misses Primary Endpoint

Dec 22

Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans

Nov 06
Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans

Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)

Oct 18

Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Oct 02
Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Jul 26
Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Jun 19
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials

Jun 07

New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

May 14
New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Feb 08
Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Dec 20
Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Nov 24
Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Oct 27
Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Aug 25
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

May 10
What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Apr 23
We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Mar 01
Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

Dec 28
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

CEO Compensation Analysis

How has Gene Kinney's remuneration changed compared to Prothena's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$110m

Dec 31 2024US$7mUS$654k

-US$122m

Sep 30 2024n/an/a

-US$132m

Jun 30 2024n/an/a

-US$51m

Mar 31 2024n/an/a

-US$172m

Dec 31 2023US$7mUS$631k

-US$147m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$141m

Mar 31 2023n/an/a

-US$128m

Dec 31 2022US$7mUS$601k

-US$117m

Sep 30 2022n/an/a

-US$156m

Jun 30 2022n/an/a

-US$1m

Mar 31 2022n/an/a

US$67m

Dec 31 2021US$5mUS$573k

US$67m

Sep 30 2021n/an/a

US$69m

Jun 30 2021n/an/a

-US$70m

Mar 31 2021n/an/a

-US$124m

Dec 31 2020US$3mUS$554k

-US$111m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$91m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$3mUS$538k

-US$78m

Sep 30 2019n/an/a

-US$79m

Jun 30 2019n/an/a

-US$84m

Mar 31 2019n/an/a

-US$128m

Dec 31 2018US$11mUS$525k

-US$156m

Compensation vs Market: Gene's total compensation ($USD7.23M) is above average for companies of similar size in the US market ($USD2.75M).

Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.


CEO

Gene Kinney (55 yo)

8.7yrs

Tenure

US$7,230,959

Compensation

Dr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...


Leadership Team

NamePositionTenureCompensationOwnership
Gene Kinney
President8.7yrsUS$7.23m0.024%
$ 95.1k
Tran Nguyen
CFO & Chief Strategy Officer12.2yrsUS$2.59m0.0041%
$ 16.4k
Brandon Smith
Chief Operating Officer3.6yrsUS$2.50m0%
$ 0
Wagner Zago
Chief Scientific Officer7.9yrsUS$2.41m0%
$ 0
Carol Karp
Chief Regulatory Officer8.4yrsUS$2.44m0%
$ 0
Karin Walker
Chief Accounting Officer & Controller12yrsno datano data
Mark Johnson
Vice President of Investor Relationsno datano datano data
Michael Malecek
Chief Legal Officer & Company Secretary5.8yrsUS$1.18mno data
David Ford
Chief People Officer1.2yrsno datano data
Chad Swanson
Chief Development Officerless than a yearno datano data

7.9yrs

Average Tenure

54.5yo

Average Age

Experienced Management: PRTA's management team is seasoned and experienced (7.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gene Kinney
President8.7yrsUS$7.23m0.024%
$ 95.1k
Helen Kim
Independent Director2.8yrsUS$288.01k0%
$ 0
Richard Collier
Independent Director12.4yrsUS$302.64k0.0023%
$ 9.0k
Daniel Welch
Independent Chairman1.3yrsUS$2.67m0%
$ 0
Lars Ekman
Independent Chair Emeritus20yrsUS$304.85k0.00045%
$ 1.8k
Shane Cooke
Independent Director12.4yrsUS$309.96k0%
$ 0
Dennis Selkoe
Independent Director11.8yrsUS$297.94k0.0078%
$ 31.3k
Paula Cobb
Independent Director5.8yrsUS$304.35k0%
$ 0
William Dunn
Independent Director2yrsUS$288.44k0%
$ 0

8.7yrs

Average Tenure

64yo

Average Age

Experienced Board: PRTA's board of directors are considered experienced (8.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 04:44
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prothena Corporation plc is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Tazeen AhmadBofA Global Research
null nullBTIG